Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8551 to 8565 of 8915 results

  1. Social and emotional wellbeing in primary education (PH12)

    This guideline has been updated and replaced by the NICE guideline on social, emotional and mental wellbeing in primary and secondary education (NG223).

    Withdrawn guideline

  2. Lutonix drug-coated balloon for peripheral arterial disease (MIB72)

    NICE withdrew this medtech innovation briefing in October 2019 after the MHRA withdrew support for this type of technology being used in intermittent claudication for arterial disease.

    Withdrawn advice

  3. Ultroid 2.0 for internal haemorrhoids (MIB75)

    This medtech innovation briefing is temporarily unavailable, please contact mibs@nice.org.uk for further information.

    Withdrawn advice

  4. Endoluminal gastroplication for gastro-oesophageal reflux disease (IPG404)

    Interventional procedures, IPG404 - Issued: July 2011 --> This guidance has been updated and replaced by NICE HealthTech guidance 661.

    Withdrawn guidance

  5. Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension (IPG418)

    Interventional procedures, IPG418 - Issued: January 2012 --> This guidance has been updated and replaced by NICE HealthTech guidance 662.

    Withdrawn guidance

  6. Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

    Discontinued Reference number: GID-DT9

    Diagnostics guidance
    Discontinued

  7. Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

    Discontinued Reference number: GID-TA10598

    Technology appraisal guidance
    Discontinued

  8. Colon cancer (adjuvant) - irinotecan [ID379]

    Discontinued Reference number: GID-TAG380

    Technology appraisal guidance
    Discontinued

  9. Diabetic retinopathy - ruboxistaurin [ID382]

    Discontinued Reference number: GID-TAG386

    Technology appraisal guidance
    Discontinued

  10. Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

    Discontinued Reference number: GID-TA10779

    Technology appraisal guidance
    Discontinued

  11. Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]

    Discontinued Reference number: GID-TA10822

    Technology appraisal guidance
    Discontinued

  12. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]

    Discontinued Reference number: GID-TA11018

    Technology appraisal guidance
    Discontinued

  13. Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]

    Discontinued Reference number: GID-TA10961

    Technology appraisal guidance
    Discontinued

  14. Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]

    Discontinued Reference number: GID-TA11166

    Technology appraisal guidance
    Discontinued

  15. Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]

    Discontinued Reference number: GID-TA11074

    Technology appraisal guidance
    Discontinued